At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
ABT-333 +3 moredrug
Likely dose
ABT-333 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Blinded, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
In Brief
A Phase 2 clinical trial evaluating ABT-333, Placebo for ABT-333, and 2 other interventions for Chronic Hepatitis C Virus Infection. Completed, enrolled 30 participants across 8 sites in 2 countries.
Detailed Summary
The purpose of this study was to assess the safety, tolerability, pharmacokinetics and antiviral activity of ABT-333 (also known as dasabuvir) in treatment-naïve, hepatitis C virus (HCV)-infected participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C Virus Infection
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2009
Enrollment StartMar 2009
Primary CompletionJul 2009
TodayJul 2026
First PostedFeb 26, 2009
Enrollment StartMar 1, 2009
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 17.3 years ago
Interventions
ABT-333drug
50 mg capsules
Placebo for ABT-333other
Capsule
Pegylated interferondrug
Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
Ribavirindrug
200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day